Madison Avenue Partners has initiated a significant new position in Indivior Plc (NASDAQ:INDV), acquiring 4,315,162 shares valued at approximately $131.53 million by the end of the first quarter. This investment represents a 6.2% increase in the fund’s reportable U.S. equity assets under management, highlighting a strategic bet on Indivior’s growth potential in the opioid treatment market.
Indivior’s stock has surged nearly 200% over the past year, significantly outperforming the S&P 500’s 28% gain. This remarkable performance is underpinned by strong revenue growth, particularly from its long-acting opioid treatment, SUBLOCADE, which saw first-quarter revenue rise by 32% year-over-year. The company has also raised its full-year guidance, projecting SUBLOCADE revenue could reach up to $990 million in 2026, reflecting robust demand in an underserved market.
For market professionals, the key takeaway is that Madison Avenue Partners’ investment signals confidence in Indivior’s ability to sustain its growth trajectory, particularly through SUBLOCADE. However, the concentration of revenue from this single product poses risks that investors should carefully evaluate.
Source: nasdaq.com